Introduction
In chronic kidney disease (CKD), metabolic changes and disturbances in the urinary excretion of metabolites cause the accumulation of uremic toxins in the body (Vanholder et al., 2001; Vanholder et al., 2007; Liabeuf et al., 2010) . Among the uremic toxins, sulfate conjugated substances, p-cresyl sulfate (PCS) and indoxyl sulfate (IS), are prototypic proteinbound uremic toxins (Fig. 1) . Recently, Liabeuf et al. evaluated whether free and total serum PCS concentrations were associated with vascular calcification, arterial stiffness and mortality risk in a cohort of CKD patients (Liabeuf et al., 2010) . They concluded that while serum concentrations of free and total PCS were elevated in the latter stages of CKD, only free PCS seemed to be a reliable predictor of survival in CKD. In fact, the higher free PCS concentrations were associated with mortality and this was independent of the well-known predictors of survival such as age, vascular calcification, anemia and inflammation. Wu et al. also found that a high serum concentration of free PCS was independently associated with increased risk of general mortality and cardiovascular mortality in Asian elderly hemodialysis patients (Wu et al.) . Moreover, hemodialysis does not efficiently remove PCS from the body because it binds to albumin (Martinez et al., 2005) . In fact, Meyer et al. elaborated a mathematical model describing the behavior of protein-bound uremic toxins during hemodialysis. In their model, clearance is directly associated with the free fraction of PCS (Meyer et al., 2004) . Based on these data, the serum concentrations of PCS, especially its free concentration, could be associated with CKD progression, cardiovascular outcomes and the efficacy of hemodialysis. Therefore, it is of interest to clarify the factors that determine changes in the free concentration of PCS in CKD patients.
In general, the changes in free concentration of substances in serum could be explained by the alternation of their disposition in body, for instance interactions with other molecules that concomitantly existed. In fact, we previously demonstrated that PCS, like IS, This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on April 18, 2012 as DOI: 10.1124 at ASPET Journals on April 14, 2017 dmd.aspetjournals.org Downloaded from DMD #45617 5 was a substrate for organic anion transporters (OATs) , and we found the possibility that competitive interaction between these two toxins takes place during the renal uptake process that can influence fluctuations in their respective serum concentration.
In addition, changes in the free concentration of PCS induced by IS could be the result of displacement of protein bound PCS in the serum, especially from human serum albumin (HSA) . HSA has at least two distinct binding sites for endogenous and exogenous substances, including drug; site I in subdomain 2A (also known as the warfarin binding site), and site II in subdomain 3A (also known as the indole and benzodiazepine binding site) (Kragh-Hansen, 1981) . Competitive experiments (Sakai et al., 1995) and X-ray crystallographic analyses (Ghuman et al., 2005) demonstrated that the high affinity binding site of IS was site II on HSA. Several observations have been reported for serum protein binding of PCS. For instance, Meijers et al. conducted in vitro spiking experiments using serum from hemodialysis patients and found that the addition of IS significantly increased the free concentration of PCS and vice versa . Loor et al. also reported that sodium octanoate, a medium chain fatty acid that binds to site II, inhibited the binding of PCS and IS to uremic and normal serum ). These findings suggest that PCS and IS may share the same binding site on HSA. However, the binding characteristics of PCS to HSA and its potential interaction with IS on HSA have not been fully elucidated.
The aim of this study was to characterize the binding of PCS to HSA and also establish whether PCS interacts with IS and vice versa in the binding to HSA. First, we determined the binding parameters of PCS to HSA using an ultrafiltration method. We also identified the binding site of PCS using a site marker displacement method in conjunction with experiments using a mutant HSA that displayed reduced ligand binding. Furthermore, we attempted to characterize the interaction between PCS and IS in terms of their binding to HSA using a competitive interaction model. Based on our findings, together with previously This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Chemicals and materials
PCS was synthesized according to the method of Feigenbaum and Neuberg (Feigenbaum and Neuberg, 1941) . The identity and purity (>99%) of PCS was confirmed by nuclear magnetic resonance (NMR) spectroscopy. Warfarin (WF), dansylsarcosine, indoxyl sulfate (IS), hippurate (HA) (Sigma-Aldrich, St. Louis, MO) and indoleacetic acid (IA) (Nacalai Tesque Inc., Kyoto, Japan) were obtained as pure substances from the respective manufacturers. 3-carboxy-4-methyl-5-propyl-2-furan propionate (CMPF) was synthesized as described previously (Tsutsumi et al., 2002) . All reagents from commercial sources were of the highest grade.
Determination of ligand binding parameters
A quantitative analysis of potential interaction between ligands bound to HSA was performed by ultrafiltration. The ultrafiltration was carried out using an Amicon ultra-0.5 micropartition system with a YM-30 ultrafiltration membrane. HSA and ligands were dissolved in PBS (pH 7.4). Samples of 250 μ L were ultrafiltered at 25 ℃ , 10,000 g for 3 min. Free ligand concentrations were measured by HPLC. In the ultrafiltration method, bound ligand concentration (C b ) was calculated using the following equation:
where C t and C f are total and free ligand concentration, respectively.
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where r is the number of moles of bound drug per mole of protein; n i is the number of binding sites per protein molecule and K i is the binding constant in the i th binding class.
If the HSA has only one kind of binding site for ligand (n=1), the above equation can be converted to Klotz equation as follows;
HPLC conditions
The HPLC system consisted of an Agilent 1100 series intelligent pump and a fluorescence spectrophotometer. A LiChrosorb RP-18 column (Cica Merk, Tokyo, Japan) was used as the stationary phase. The mobile phase consisted of (A) 100% methanol and (B) 50 mM ammonium formate (pH 4.0). Bound material was eluted using a linear gradient of 65-25% B from 0-15 min and then 25-65% B from 15-20 min. The column was then re-equilibrated for 2 min. The flow rate was 1.0 mL/min. PCS was detected by means of a fluorescence monitor.
The excitation/emission wavelengths were 214/306 nm, respectively (Martinez et al., 2005) . HSA ratio was kept at 1:10, respectively, in order to keep the non-specific binding of probes to a minimum. The percentage of displacement of the probe was determined according to the method of Sudlow et al. (Sudlow et al., 1975) .
where F 1 and F 2 represent the fluorescence of the probe plus HSA without or with uremic toxin, respectively.
Preparation of HSA mutant
R410A/Y411A mutant was prepared as described previously (Watanabe et al., 2000) .
Statistical analysis
Statistical analyses were performed by using one-way analysis of variance (ANOVA). A probability value of P < 0.05 was considered to be significant. , which is one order greater than that obtained in this study (Sakai et al., 1995) . In the present study we used phosphate buffered saline (PBS) because we wanted to mimic the physiological conditions. However, Sakai et al. used 67 mM phosphate buffer that did not contain any chloride ions. When we determined the binding constant of PCS in 67 mM phosphate buffer as Sakai et al., it was observed that the primary binding constant of PCS was in the order of 10 6 M -1 (data not shown). Since, it was also reported that chloride ions reduce drug binding to HSA (Wilting et al., 1980; Otagiri et al., 1989) , the difference in the binding constant of PCS to HSA between these two buffer solutions may arise from he presence or absence of sodium chloride.
Identification of the binding site of PCS using a displacement fluorescence method
In order to identify the binding site of PCS on HSA we performed site marker displacement experiments using representative fluorescent probes, warfarin (site I probe) and dansylsarcosine (site II probe) based on the method of Sudlow et al. (Sudlow et al., 1975) . The results were compared to those of other uremic toxins (IS, CMPF, IA and HA) (Sakai et al., 1995) . As shown in Figure 2 , warfarin was significantly displaced by CMPF This article has not been copyedited and formatted. The final version may differ from this version. alone, while IS and IA caused a slight enhancement in the fluorescence of the warfarin-HSA complex ( Fig. 2A ). PCS and HA had no effect on the fluorescent properties of the warfarin-HSA complex. By contrast, the fluorescence of dansylsarcosine was markedly decreased in the presence of IS, PCS and IA, although to varying extents (Fig. 2B) . Moreover, the displacement behavior of IS, CMPF, IA and HA were entirely consistent with our previous results (Sakai et al., 1995) . These data suggested that PCS bound to site II on HSA.
Binding of PCS to wild-type or mutant HSA
We have previously demonstrated that Arg410 and Tyr411 play an important role in ligand binding to site II of HSA (Watanabe et al., 2000) . Thus, simultaneous substitution of Arg410 and Tyr411 in HSA for alanine (R410A/Y411A) significantly reduced the binding of site II specific ligands (Watanabe et al., 2000) . To confirm the results obtained by the fluorescence displacement method, the binding of PCS and IS to HSA were further determined using the mutant HSA (R410A/Y411A). As shown in Figure 3 , substituting Arg410 and Tyr411 for the relatively small amino acid alanine decreased the bound percentage of PCS from 80% for wild-type HSA to 58% for the mutant HSA. In the case of IS, the bound percentage was decreased from 78% for wild-type HSA to 47% for mutant HSA. These data indicated that Arg410 and Tyr411 play an important role for the binding of PCS to HSA as well as IS and strongly suggested that PCS bound to site II on HSA.
Furthermore, this decrease in PCS binding was smaller than that observed for IS. 
Interaction of PCS and IS in HSA binding
Previously, it was reported that serum concentrations of PCS and IS were increased to the range of 100-500 μM and 100-1000 M in patients with CKD stage 4-5, respectively (Vanholder et al., 2003) .
To further investigate whether competitive interaction of PCS and IS occurs under Similarly, the free percentage of IS to HSA also increased in the presence of PCS, in a concentration-dependent manner (Fig. 5B ). These data indicated that PCS and IS mutually inhibited HSA binding under the serum concentration range observed in patients with CKD stage 4-5. Moreover, PCS was superior to IS in terms of displacement ability with respect to binding HSA. Our results from fluorescent probe displacement experiments using warfarin and dansylsarcosine, as site I and II marker probes, respectively, suggest that the high affinity binding site of PCS is site II. This idea was supported by the fact that PCS binding to HSA was significantly decreased when the amino acid residues Arg410 and Tyr411 were concurrently mutated to Ala. We have already demonstrated that these two amino acids play an important role in drug binding, including IS, to site II of HSA (Watanabe et al., 2000) .
These findings suggest that PCS and IS share the same high affinity binding site on HSA. In fact, Klotz analysis shows that IS inhibits PCS binding to HSA in a competitive manner. Our proposal is consistent with previous experimental findings that showed: (i) addition of IS into the serum from hemodialysis patients significantly increased the free concentration of PCS and vice versa (Sakai et al., 1995) . They concluded that IA, IS and HA bound to site II, whereas CMPF specifically interacted with site I. Based on these findings, we can anticipate that PCS, like IS, interacts with HA and IA for binding HSA.
Although IS and PCS share the same high affinity binding site on HSA, the displacement of IS by PCS was greater than that of PCS by IS (Fig. 5) . As shown in Table 1 , the binding constant of high affinity site for PCS (1 x 10 5 M -1
) was similar to that of IS, while the binding constant of low affinity site for PCS (K 2 =19.6 x 10 3 M -1 ) was 2.5-fold greater than that of IS (K 2 =8 x 10 3 M -1
). The difference in binding ability at this site may explain why PCS displaces IS more strongly than IS displaces PCS (i.e., if the low binding site is shared by these two uremic toxins).
Our present data showed the binding constant of high affinity site on HSA for PCS PCS between the present study and that of Berge-Lefrank et al. may arise from differences in the experimental methods for estimating binding constant of PCS (ultrafiltration vs microcalorimetry). In addition, we used the PCS concentration from 7.5 to 500 μM to estimate the binding constant, while Bergé-Lefranc et al. used from 500 μM to 12 mM. This indicated that PCS concentrations used in our study is closer to the concentrations observed in CKD patients (100-500 μM) than that in Bergé-Lefranc's study.
Pathophysiological implications
Because PCS is mostly bound to serum proteins, especially HSA, any changes in the level of HSA will influence the free concentration of PCS. Additionally, it is possible that interaction with IS during the disposition of PCS around the body may also alter its free concentration. We previously reported that IS is a substrate of OAT1 and OAT3, which are expressed on the basolateral side of the proximal renal tubules (Deguchi et al., 2004; Deguchi et al., 2005a; Deguchi et al., 2005b) . In addition, rat renal cortical slice experiments demonstrated that the OAT system plays an important role in the basolateral uptake of PCS in the kidney . Importantly, PCS uptake was significantly inhibited in the presence of IS. Thus, increased serum concentrations of IS are accompanied by impaired renal function, which can contribute to the inhibition of the renal excretion of PCS and vice versa via OAT. Therefore, we propose that PCS and IS can also interact during renal uptake, leading to fluctuations in their serum concentrations. So far, there is no information regarding the interaction between IS and PCS during the absorption process or in their biosynthetic pathways, despite the fact that both toxins undergo sulfate conjugation. It is believed that IS is sulfated in the liver, while PCS is sulfated by an intestinal specific sulfotransferase . Therefore, PCS is unlikely to interact with IS during its biosynthesis.
Furthermore, it is also believed that IS and PCS are metabolic end products (Watanabe et al., This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 6 ). Such interaction with IS could influence fluctuations in the free concentration of PCS in CKD patients.
Recent clinical studies have shown that elevated levels of free PCS in the serum are associated with mortality in a cohort of CKD patients (Liabeuf et al., 2010; Wu et al.) .
Meijers et al. demonstrated that serum free PCS and IS concentrations were significantly related, whereas serum total PCS and IS concentrations were not related 
